Skip to main content
ADAG
NASDAQ Life Sciences

Adagene Completes Phase 2 Enrollment, Triggering $8M Sanofi Second Closing

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$2
Mkt Cap
$161.815M
52W Low
$1.3
52W High
$4.85
52W Position info
54% above low
Off High info
59% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

ADAG sits 54% above its 52-week low of $1.3.

Summary

Adagene completed enrollment of 60 patients in its randomized Phase 2 muzastotug/KEYTRUDA trial in MSS colorectal cancer, satisfying the milestone for Sanofi's US$8.0 million second closing around November 20, 2026 and bringing Sanofi's total investment to US$25.0 million. Initial dose-optimization results are expected in 1H 2027 to set the Phase 3 regimen.


Key Events · M&A and Partnerships · ADAG

  • Phase 2 Enrollment Complete

    All 60 patients have been enrolled and randomized 1:1 across two muzastotug dosing arms combined with pembrolizumab in late-line MSS colorectal cancer without liver metastases.

  • Sanofi Second Closing Triggered

    The enrollment milestone satisfies the condition for Sanofi's US$8.0 million second closing, expected on or around November 20, 2026, via 378,788 additional Series A Preferred Shares.

  • Total Sanofi Commitment $25M

    Combined with the US$17.0 million first closing on July 2, 2025 (1,062,500 preferred shares), Sanofi's total investment under the June 30, 2025 securities purchase agreement reaches US$25.0 million.

  • Dose Data Due 1H 2027

    Initial results from the randomized dose-optimization trial are expected in the first half of 2027 and will inform the dose regimen for the Phase 3 registration trial.


Analysis · ADAG · Life Sciences

The contractual milestone for Sanofi's second tranche has been met: Adagene finished enrolling all 60 patients in the randomized Phase 2 dose-optimization trial of muzastotug plus KEYTRUDA in late-line MSS colorectal cancer. That unlocks US$8.0 million on or around November 20, 2026 and lifts Sanofi's total commitment to US$25.0 million — non-dilutive-to-cash runway support at a company that reported US$127.9M in cash in August. The trade-off is dilution: 378,788 Series A Preferred Shares convert into roughly 3.79 million ordinary shares, against 1,062,500 preferred issued in the July 2025 first closing. The real value driver is the readout: initial dose-optimization data in 1H 2027 will pick the regimen for the Phase 3 registration trial, where the FDA has already agreed on an OS primary endpoint and a standard-of-care control arm without a monotherapy arm.

How filings like this one have moved

In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ADAG was trading at $2.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $161.8M. The 52-week trading range was $1.30 to $4.85. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ADAG - Latest Insights

ADAG
Nov 09, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.00
Real-time Price: $2.00 info
Change: $0 (0%) info
Market Cap: $161.815M info
ADAG
Sep 22, 2026, 8:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $3.21
Real-time Price: $2.00 info
Change: -$1.21 (-38%) info
Market Cap: $161.815M info
ADAG
Sep 22, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.21
Real-time Price: $2.00 info
Change: -$1.21 (-38%) info
Market Cap: $161.815M info
ADAG
Aug 12, 2026, 7:30 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $3.80
Real-time Price: $2.00 info
Change: -$1.80 (-47%) info
Market Cap: $161.815M info
ADAG
Aug 12, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.80
Real-time Price: $2.00 info
Change: -$1.80 (-47%) info
Market Cap: $161.815M info